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Abstract
Background: The use of HbA1c ≥6.5% for diagnosis of diabetes has been challenged for post-transplantation
diabetes mellitus (PTDM) also known as new onset diabetes after transplantation (NODAT) due to a low sensitivity
early after renal transplantation. PTDM diagnosed with an oral glucose tolerance test (OGTT) is highly predictable for
long-term patient mortality. HbA1c was introduced for diagnosis based on the risk of developing diabetic retinopathy.
The utility of HbA1c measures versus glucose criteria has not been widely assessed in stable transplant patients but still
HbA1c is widely used in this population. The aim of the present analyses was to validate the utility of fasting plasma
glucose (FPG) together with HbA1c in diagnosing PTDM in stable renal transplant recipients (RTRs).
Methods: OGTT’s were performed one year after transplantation in 494 consecutive RTRs without diabetes. FPG and
HbA1c were obtained the same day, before starting the OGTT. Validation was performed using C-statistics and logistic
regression analyses.
Results: PTDM was diagnosed in 51 patients (10.3%) by glucose criteria, 38 (74%) patients were diagnosed by FPG
≥7.0 mmol/L [126.1 mg/dl], and 13 (26%) only by 2-h plasma glucose. Six of the latter had HbA1c ≥6.5%. Only seven
patients out of the 51 (13.7%) PTDM patients remained undiagnosed when HbA1c ≥6.5% was used together with FPG,
and five of these regressed to normal after a median follow-up of 14months. ROC curves including FPG and HbA1c
versus OGTT derived criteria revealed an AUC of 0.858.
Conclusions: Combining standard diagnostic FPG and HbA1c criteria captured almost all patients with persistent
PTDM in stable RTRs. The combined use of the criteria appears to be an applicable diagnostic strategy for PTDM
without the need of an OGTT one year post-transplant.
Trial registration: Retrospectively registered.
Keywords: Renal transplantation, Post-transplantation diabetes mellitus, Diagnosis, Oral glucose tolerance test, HbA1c
* Correspondence: aussif@hotmail.com
1Department of Transplantation Medicine, Oslo University Hospital,
Rikshospitalet, P.O.Box 4950, 0424 Oslo, Nydalen, Norway
Full list of author information is available at the end of the article
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Ussif et al. BMC Nephrology           (2019) 20:12 
https://doi.org/10.1186/s12882-018-1171-3
Background
Post-transplantation diabetes mellitus (PTDM) is a term
for diabetes that is diagnosed after solid organ transplant-
ation. The diagnosis has traditionally been based on glu-
cose criteria according to an oral glucose tolerance test
(OGTT) [1]. However, with the introduction of HbA1c
≥6.5% as a diagnostic measure for type 2 diabetes [2, 3]
questions have been raised regarding the use of this criter-
ion also for PTDM, at least after renal transplantation [4–
6]. While the PTDM diagnosis made by the glucose criter-
ion primarily defines increased mortality risk for the pa-
tient [7], the HbA1c criterion in type 2 diabetes is chosen
merely according to the risk of developing diabetic retin-
opathy [8]. Other arguments against the use of HbA1c are
particularly relevant to the early phase following renal
transplantation with changes in erythropoiesis and intro-
duction of anti-proliferative immunosuppressive drugs
amongst other interacting factors on HbA1c [4, 6]. In
agreement with these notions a previous study of early
PTDM after renal transplantation revealed that the sensi-
tivity of HbA1c ≥6.5% was as low as 50% for the diagnosis
of PTDM [9]. When the glucose criteria during OGTT for
the diagnosis of PTDM were used, we confirmed previous
findings that PTDM had a detrimental effect on
long-term cardiovascular outcomes, but HbA1c ≥6.5% per
se did not significantly associate with adverse outcomes
[7]. Other investigators have argued that a cut-off value
for HbA1c ≥6.2% may be reasonable for diagnosis of
PTDM in the early phase after transplantation [10]. A
combination of the HbA1c criteria and OGTT in high risk
patients may be another approach as advocated by an
international consensus meeting on PTDM [11]. However,
there is probably need for a simplified strategy in daily
clinical routine.
It is conceivable that HbA1c associates better with
glucose long-term than the first months after transplant-
ation. One year after transplantation hemoglobin values
are usually normalized and stable in successfully RTRs.
During the last few years we have examined almost
RTRs at 1 year after transplantation, and included
OGTTs for PTDM in patients who did not have a
diagnosis of PTDM at this time point. The aims of
this study were to examine whether the HbA1c cri-
teria were useful for the diagnosis of PTDM and
whether a combination of FPG and HbA1c drawn in
a single fasting state could be used for diagnosis
without need for an OGTT in a stable phase after
renal transplantation.
Methods
All renal transplantations in Norway are performed at
the National Transplant center in Oslo. As part of the
routine follow-up most patients return to the transplant
center after 1 year for thorough investigations including
an OGTT. Only patients without prior diagnosis of
diabetes or PTDM undergo the glucose challenge test at
that time. In the time period between September 2012
and August 2016 a total of 950 patients over 18 years of
age were transplanted and 647 patients were attending 1
year follow-up. Altogether 494 patients without diabetes
underwent testing with valid results from the OGTT 1
year after transplantation. The disposition of the patients
is shown in Fig. 1.
The immunosuppressive protocol consisted of basilixi-
mab (20 mg iv on day 0 and 4) and methylprednisolone
(250/500 mg iv on day 0 in standard/high risk patients)
induction, followed by tacrolimus, mycophenolate mofe-
til and prednisolone maintenance. Oral tacrolimus was
initiated at the day of transplantation, starting with
0.04 mg/kg twice daily in standard risk patients and
Fig. 1 Patient disposition chart
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0.05 mg/kg twice daily in high risk patients. TDM was
applied and doses were adjusted to reach target whole
blood trough concentrations of 3 to 7 μg/L in stand-
ard immunological risk patients, and 8 to 12 μg/L
(days 0–30) followed by 6 to 10 μg/L (after day 30) in
high immunological risk patients. The mycophenolate
mofetil dose was 750 mg twice daily and prednisolone
was given once daily, 20 mg on day 1 (80 mg in high
risk patients), and tapered to 10 mg at 4 weeks in
standard risk and 8 weeks in high risk patients.
Clinical and laboratory data were retrospectively re-
trieved from the clinical biobank and the Norwegian
Renal Registry. All patients had signed an informed con-
sent for use of the data for research purposes concerning
outcomes after renal transplantation and the Regional
Ethics Committee for South-East Norway had approved
studies on outcomes in this population.
Statistical methods
Characteristics of the sample population were presented
and subgroups were compared based on glucose criteria.
Differences within the three subgroups were tested using
the ANOVA test for continuous variables and the
Chi-square test for categorical variables. Logistic regres-
sion was conducted using HbA1c and FPG as the covari-
ates vs 2hPG (OGTT) as the dependent variable.
Furthermore, ROC curve analysis was conducted and
sensitivity, specificity, positive predictive value (PPV)
and negative predictive value (NPV) calculated. All ana-
lyses were conducted using IBM SPSS release 24.0.0.1
and R version 3.4.3 [12].
Results
Demographic data of the study population and subgroups
according to glucose tolerance; normal glucose tolerance
(NGT), impaired glucose tolerance (IGT) and diabetes
(PTDM) are shown in Table 1. Two thirds of the recipi-
ents were males with ages ranging from 18 to 82 years.
Almost a third of the patients had living donors.
Diagnosis of PTDM by glucose criteria
Table 1 reveals the differences between the glucose toler-
ance groups based on the OGTT. There was a signifi-
cant difference in age between the groups, the PTDM
Table 1 Demographic and clinical characteristics of 494 patients by glucose tolerance subgroups
All patients NGT IGT PTDM P-value
Number of patients 494 377 66 51
Age (years) 52.5 ± 14.0 50.5 ± 14.2 58.1 ± 10.8 60.6 ± 11.4 < 0.001
Donor (% living) 152 (30.8) 121 (32.1) 22 (33.3) 9 (17.6) 0.10
Gender (% males) 343 (69.2) 251 (66.6) 51 (77.3) 39 (76.5) 0.11
BMI (kg/m2) 25.9 ± 4.5 25.5 ± 4.4 26.4 ± 4.5 27.4 ± 5.1 0.01
Hemoglobin (g/dL) 13.7 ± 1.7 13.7 ± 1.7 13.7 ± 1.7 13.8 ± 1.6 0.83
HbA1c (%) 5.6 ± 0.5 5.5 ± 0.4 5.9 ± 0.4 6.4 ± 0.7 < 0.001
Fasting plasma glucose
(mmol/L) 5.6 ± 0.9 5.4 ± 0.5 5.8 ± 0.5 7.4 ± 1.0 < 0.001
[mg/dL] [100.9 ± 16.2] [97.3 ± 9.0] [104.5 ± 9.0] [133.3 ± 18.0]
2 h plasma glucose after OGTT
(mmol/L) 6.7 ± 2.5 5.6 ± 1.1 8.9 ± 0.9 11.3 ± 3.6 < 0.001
[mg/dL] [117.1 ± 45.0] [100.9 ± 19.8] [160.4 ± 16.2] [203.6 ± 64.9]
Creatinine (μmol/L) 117 ± 40 115 ± 38 125 ± 46 118 ± 45 0.20
Total cholesterol
(mmol/L) 4.9 ± 1.0 4.8 ± 1.0 5.1 ± 1.1 5.0 ± 1.0 0.10
[mg/dL] [88.3 ± 18.0] [86.5 ± 18.0] [91.9 ± 19.8] [90.1 ± 18.0]
LDL-cholesterol
(mmol/L) 2.9 ± 0.9 2.8 ± 0.8 3.0 ± 0.9 2.9 ± 0.9 0.17
[mg/dL] [52.3 ± 16.2] [50.5 ± 14.4] [54.1 ± 16.2] [52.3 ± 16.2]
Triglycerides
(mmol/L) 1.6 ± 0.8 1.5 ± 0.8 1.8 ± 1.0 2.0 ± 1.0 < 0.001
[mg/dL] [28.8 ± 14.4] [27.0 ± 14.4] [32.4 ± 18.0] [36.0 ± 18.0]
Difference between subgroups given in mean ± standard deviation or number (%), evaluated by the ANOVA test for continuous variables and Pearson chi-square
test for categorical variables. P-values are reported to 2 decimals. Abbreviations: BMI, body mass index in kg/m2; IGT impaired glucose tolerance, LDL low density
lipoprotein, NGT normal glucose tolerance, OGTT oral glucose tolerance test, PTDM post-transplantation diabetes mellitus
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patients were 10 years older than NGT patients and had
slightly higher BMI. Beyond the difference in glucose
measures also HbA1c and lipid profiles were different
between the groups. A total of 51 patients (10.3%) were
diagnosed with PTDM by the glucose criteria.
The diagnosis of PTDM was obtained by FPG ≥7.0
mmol/L [126.1 mg/dL] in 38 out of 51 patients (74%).
The remaining 13 patients that had FPG < 7.0 mmol/L
[126.1 mg/dL] were diagnosed by isolated 2-h plasma
glucose (2hPG) ≥11.1 mmol/L [200.0 mg/dL] following
OGTT. The overlap of glucose criteria in the PTDM
patients is illustrated in Fig. 2. Among those with
PTDM 21 (41%) had HbA1c ≥6.5% and 30 (59.0%)
had HbA1c ≥6.2%.
Sixty-six (13.4%) patients were diagnosed with IGT
and among those 443 without diabetes 5 (1.1%) had
HbA1c ≥6.5% and 18 (4.0%) had HbA1c ≥6.2%).
Diagnosis of PTDM by HbA1c criteria
Table 2 shows the sensitivity, specificity, positive- and
negative predictive values for different cut-off values of
HbA1c for the diagnosis of PTDM. The sensitivity for the
HbA1c criteria for a diagnosis of PTDM was 43% for
HbA1c ≥6.5 and 69% for HbA1c ≥6.2%. However, the spe-
cificity of the diagnosis was 97% with HbA1c ≥ 6.5% versus
88% for HbA1c ≥6.2%. When patients with a diagnosis of
PTDM by FPG (n = 38) were taken out of the analysis the
data remained similar (sensitivity was 46% for HbA1c ≥6.5
and 69% for HbA1c ≥6.2%., specificity of the diagnosis was
98% with HbA1c ≥ 6.5% versus 90% for HbA1c ≥6.2%).
Combination of fasting plasma glucose and HbA1c
criteria
The relationship between HbA1c and 2hPG after OGTT
in patients with normal FPG (< 7.0 mmol/L) [126.1 mg/
dL] is shown in Fig. 3. This figure shows the additional
value of HbA1c for the diagnosis of PTDM, beyond what
FPG provide by itself. As seen in the upper left quadrant,
seven patients remained undiagnosed when HbA1c
≥6.5% was used as cut-off. When FPG ≥7.0 mmol/L
[126.1 mg/dL] and HbA1c ≥6.5% were combined, 44 out
of 51 (86%) PTDM patients were diagnosed. We exam-
ined the trajectories of glucose values for these seven
“false negative” patients that showed an isolated 2hPG
≥11.1 mmol/L [200.0 mg/dL]; five had a median FPG of
5.8 (range 5.7–6.1) mmol/L [102.7–109.9 mg/dL] and
median HbA1c of 5.6 (range 5.2–6.0) % after a median
observation time of 14 months (range 3–40). The two
others received oral antidiabetic medication after a mean
observation time of 18months. Eleven patients had HbA1c
≥ 6.5% without fulfilling the OGTT criteria. Five of these
had IGTand only one had a completely normal FPG.
The sensitivity was improved when the cut-off value
was lowered to HbA1c ≥6.2%. However, the number of
false positive diagnosis of PTDM increased manifold as
apparent from the lower right quadrant in Fig. 3.
Fig. 2 Venn diagram illustrating the overlap between FPG and 2hPG
as diagnostic findings in 51 PTDM patients
Table 2 Diagnostic performance of HbA1c at different cut-off
values in all 494 patients
Sensitivity (%) Specificity (%) PPV (%) NPV (%)
HbA1c ≥5.5% 88.0 44.5 15.4 97.0
HbA1c ≥6.0% 79.4 81.8 33.4 97.2
HbA1c ≥6.2% 69.0 88.1 40.0 96.1
HbA1c ≥6.5% 43.1 97.2 63.9 93.7
Abbreviations: NPV negative predictive value, PPV positive predictive value
Fig. 3 Diagram illustrating the 2-h plasma glucose versus HbA1c
values in all 456 patients after removal of 38 patients diagnosed
with PTDM using FPG criteria
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To further demonstrate the utility of our results we
conducted a multivariate ROC analysis as shown in Fig.
4. Combining information from both FPG and HbA1c
variables in the logistic regression on a patient improved
the AUC from 0.800 (see Fig. 5) to 0.856. That is the dis-
criminatory power has improved by 5.6%.
Discussion
The novel aspect of the present study is that the stand-
ard diagnostic criteria with FPG ≥7.0 mmol/L [126.1 mg/
dL] used in combination with HbA1c ≥6.5% allows for a
simplified diagnostic strategy that captures almost all
patients with persisting PTDM in a stable phase 1 year
after renal transplantation. Comprising almost 500
patients, this study is to our knowledge the biggest ad-
dressing the use of HbA1c as a supplementary diagnostic
tool together with FPG. When this approach was used,
seven out of 51 patients were missed, but upon further
follow-up of these patients five regressed to normal glu-
cose tolerance after 14 months. Only two patients had
persisting PTDM and later received oral antidiabetic
medication. On the other hand; eleven false positive
patients were diagnosed with PTDM when the HbA1c
criterion was used, as they showed 2hPG < 11.1 mmol/L
[200.0 mg/dL] following OGTT. This may not be a chal-
lenge since they initially would not need drugs or any
particular counseling beyond normal practice. When the
cut-off was lowered to HbA1c ≥6.2%, in accordance to
what has also been advocated for PTDM in an early
phase after transplantation [10], the sensitivity was
slightly higher but the number of false negatives in-
creased manifold. Again we have demonstrated the ap-
plication of ROC analysis to two quantitative tests that
is HbA1c and FPG in this paper. The model can further
be extended to include additional variables such as age
and other demographic factors.
The limitations for use of HbA1c for the diagnosis of
PTDM have been discussed extensively in the literature
[4, 5, 9, 10]. Different recommendations have been put
forward for PTDM, such as a combination of HbA1c
criteria and OGTT in high risk patients [11], random
plasma glucose measurements [13] or OGTT with
slightly elevated FPGs > 5.1 mmol/L [91.9 mg/dL] [14, 15].
The idea with the present study was to evaluate an even
simpler strategy that did not include new tests, new
algorithms or altered practice but simply evaluate the
utility of the combined diagnostic criteria in a single
fasting blood sample. There is probably no single
strategy without using an OGTT that can allow for a
correct diagnosis of all patients with PTDM even in a
stable phase after renal transplantation. The most im-
portant issue is of course the trajectory of the disease
and finally the outcomes for the patients. With the
present strategy we found that five of the patients
who missed a diagnosis had regressed to normal glu-
cose tolerance after more than 1 year of observation.
Using a lower HbA1c cut-off would retrieve more
PTDM patients but a substantial number of patients
would then have a false diagnosis that may not feel
appropriate. With the generally recommended HbA1c
limit of 6.5% a persistent PTDM diagnosis was only
missed in two out of 494 patients that underwent
Fig. 4 Combined ROC curve fasting plasma glucose and HbA1c as
predictors. Logistic regression coefficients for HbA1c and FPG with
p-values are β = 2.24(0.001) and 1.82(0.007) respectively
Fig. 5 ROC curve for HbA1c alone as predictor
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OGTT. However, we could not evaluate the trajectory
for patients with IGT that are potentially at risk for
future PTDM.
Strengths and weaknesses
Our study validated a simple strategy for the diagnosis
of PTDM in RTRs in a stable phase 1 year after trans-
plantation using a single fasting blood sample without
routine use of more cumbersome OGTT which has been
the gold standard. The group of patients examined is
large compared to previous studies from other groups
and representative as for a nationwide cohort of patients.
Data have also been sampled consecutively in all patients
using a similar protocol.
The number of PTDM patients is relatively low for
firm conclusions. More than 90% were Caucasians and
therefore external validation of the data is warranted.
Conclusions
Combining standard diagnostic FPG and HbA1c criteria
captured almost all patients with persistent PTDM in
stable RTRs. The combined use of the criteria appears to
be an applicable diagnostic strategy for PTDM without
the need of an OGTT 1 year posttransplant.
Abbreviations
2hPG: 2 h plasma glucose; ADA: American Diabetes Association; FPG: Fasting
plasma glucose; HbA1c: Glycated hemoglobin; IGT: Impaired glucose
tolerance; NGT: Normal glucose tolerance; NPV: Negative predictive value;
OGTT: Oral glucose tolerance test; PPV: Positive predictive value; PTDM: Post-
transplantation diabetes mellitus; RTRs: Renal transplant recipients;
WHO: World Health Organization
Acknowledgements
All employees at the Laboratory for Renal Physiology, OUS-Rikshospitalet,
Oslo, Norway.
Funding
From Internal resources from the Oslo University hospital, Oslo, Norway and
analysis was covered by budgets of the involved parties. The funding body
had no role at any stage during the preparation of this article.
Availability of data and materials
The datasets generated and analysed during the current study are not
publicly available due to restrictions in Norwegian law, but are available from
the corresponding author on reasonable request.
Authors’ contributions
AU, AÅ, AH designed the study. AU performed the analyses and wrote the
manuscript. AÅ retrieved the data from the database. AÅ, TASH, EN, AH, TJ
participated in research and critically revision the manuscript, and all authors
have accepted the final version for publication.
Ethics approval and consent to participate
The study was approved by the regional ethics committee for medical research
in Health Region South-East (2014/455). All patients had signed an informed




The authors declare that they have no competing interests.
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in
published maps and institutional affiliations.
Author details
1Department of Transplantation Medicine, Oslo University Hospital,
Rikshospitalet, P.O.Box 4950, 0424 Oslo, Nydalen, Norway. 2Department of
Pharmaceutical Biosciences, School of Pharmacy, University of Oslo, Oslo,
Norway. 3The Norwegian Renal Registry, Oslo University Hospital,
Rikshospitalet, Oslo, Norway. 4Institute of Clinical Medicine, Faculty of
Medicine, University of Oslo, Oslo, Norway. 5Metabolic and Renal Research
Group, Faculty of Health Sciences UiT, The Arctic University of Norway,
Tromsø, Norway.
Received: 28 May 2018 Accepted: 3 December 2018
References
1. Wilkinson A, Davidson J, Dotta F, et al. Guidelines for the treatment and
management of new-onset diabetes after transplantation. Clin Transpl. 2005;
19(3):291–8.
2. World Health Organization (WHO). Use of Glycated Haemoglobin (HbA1c) in
the Diagnosis of Diabetes Mellitus. Abbreviated Report of a WHO Consultation.
2011. http://www.who.int/diabetes/publications/report-hba1c_2011.pdf
(Assessed 12 Jan 2014).
3. American Diabetes Association. Executive summary: standards of medical
care in diabetes--2012. Diabetes Care. 2012;35(Suppl 1):S4–s10.
4. Hare MJ, Shaw JE, Zimmet PZ. Current controversies in the use of
haemoglobin A1c. J Intern Med. 2012;271(3):227–36.
5. Sharif A, Baboolal K. Diagnostic application of the a(1c) assay in renal
disease. J Am Soc Nephrol. 2010;21(3):383–5.
6. Yates CJ, Fourlanos S, Hjelmesaeth J, et al. New-onset diabetes after kidney
transplantation-changes and challenges. Am J Transplant. 2012;12(4):820–8.
7. Eide IA, Halden TA, Hartmann A, et al. Mortality risk in post-transplantation
diabetes mellitus based on glucose and HbA1c diagnostic criteria. Transpl
Int. 2016;29(5):568–78.
8. Colagiuri S, Lee CM, Wong TY, et al. Glycemic thresholds for diabetes-
specific retinopathy: implications for diagnostic criteria for diabetes.
Diabetes Care. 2011;34(1):145–50.
9. Eide IA, Halden TA, Hartmann A, et al. Limitations of hemoglobin A1c for
the diagnosis of posttransplant diabetes mellitus. Transplantation. 2015;
99(3):629–35.
10. Shabir S, Jham S, Harper L, et al. Validity of glycated haemoglobin to
diagnose new onset diabetes after transplantation. Transpl Int. 2013;
26(3):315–21.
11. Sharif A, Hecking M, de Vries AP, et al. Proceedings from an international
consensus meeting on posttransplantation diabetes mellitus: recommendations
and future directions. Am J Transplant. 2014;14(9):1992–2000.
12. R Core Team. R: a language and environment for statistical computing.
Vienna, Austria: R Foundation for Statistical Computing; 2017.
https://www.R-project.org/
13. Clore JN, Thurby-Hay L. Glucocorticoid-induced hyperglycemia. Endocr
Pract. 2009;15(5):469–74.
14. Caillard S, Eprinchard L, Perrin P, et al. Incidence and risk factors of glucose
metabolism disorders in kidney transplant recipients: role of systematic
screening by oral glucose tolerance test. Transplantation. 2011;91(7):757–64.
15. Bergrem HA, Valderhaug TG, Hartmann A, et al. Undiagnosed diabetes in
kidney transplant candidates: a case-finding strategy. Clin J Am Soc
Nephrol. 2010;5(4):616–22.
Ussif et al. BMC Nephrology           (2019) 20:12 Page 6 of 6
